Aug 2026· Genes· Vol 17, pp. 1057· 0 citations· 40 references
Medicine
TL;DR
This framework provides a scalable, transparent, and clinically aligned approach for LDLR VUS prioritization, generating ACMG/AMP-compatible computational evidence to support expert curation and downstream functional validation.
Abstract
Background: Variants of uncertain significance (VUS) in the LDLR gene remain a major barrier to the molecular diagnosis of familial hypercholesterolemia. Although computational approaches offer scalable prioritization, their clinical utility is limited by predictor discordance, incomplete annotations, and inflated performance arising from variant-type imbalance. We aimed to develop a calibrated, uncertainty-aware machine learning framework for LDLR VUS triage. Methods: We developed an end-to-end pipeline integrating multi-source variant annotations and 45 engineered features (expanded to 68 encoded features) to train RandomForest, XGBoost, and support vector machine models. The framework incorporates predictor concordance analysis, splice-aware annotation, and explicit uncertainty modeling. Models were trained using nested cross-validation and evaluated on an independent ClinGen FH-VCEP expert-panel dataset. Results: The XGBoost model achieved high discriminative performance (ROC-AUC up to 0.99 for all variants and ~0.97 for missense variants). Among 1092 LDLR VUS, 69% were assigned a directional classification, including 485 (44.4%) pathogenic-leaning and 268 (24.5%) benign-leaning variants. The remaining 31% were explicitly categorized as predictor-discordant (n = 170, 15.6%) or unresolved (n = 169, 15.5%), preserving uncertainty. Predictor discordance was particularly enriched among missense variants, indicating that naive aggregation of in silico predictors may lead to overclassification. Conclusions: This framework provides a scalable, transparent, and clinically aligned approach for LDLR VUS prioritization, generating ACMG/AMP-compatible computational evidence to support expert curation and downstream functional validation.
Machine learning-based annotation methods are increasingly used to assess the pathogenicity of genetic variants, but their performance at prioritizing variants for gene-level association testing remains poorly characterized. Here, to better understand and optimize for this use case, we assess variant annotations from...
Matthew Aguirre, Flaviyan Jerome Irudayanathan, M. Crow et al.· BMC Genomics· 0 citations
A probabilistic gradient boosting model on variant pathogenicity prediction that applies biological characteristics at both level of DNA and protein levels while also scaling the level of uncertainty in clinical decision making is presented.
Karthik V, S. Prejesh, Sumedh Deepak Kudale et al.· Frontiers in Digital Health· 0 citations
HBOCpred was developed to support research prioritisation of unresolved germline missense variants in a defined 17-gene study panel. Four calibrated learners provide vote states (V0–V4) and a continuous modified adaptive classifier score (SMAC). The same directional descriptors apply to labelled and unresolved records:...
M. Alay, H. Erdem· International Journal of Mol...· 0 citations
Under a leakage-controlled, unbiased evaluation, XGBoost provided moderate but trustworthy discrimination together with well-calibrated probabilities for diabetes prediction, while SHAP confirmed clinically plausible predictors.
Z. Kucukakcali, I. Cicek· International Journal of Med...· 0 citations
HeartVar demonstrates that an LLM constrained by a domain-specific prompt and grounded in structured evidence can produce variant interpretations of first-pass quality for a cardiovascular disease cohort; however, it is not intended to replace manual assessment by a qualified variant curator.
Jamie-Lee M. Thompson, Debjani Das, Sally L. Dunwoodie et al.· bioRxiv· 0 citations
ImportanceCardiovascular disease remains the leading cause of mortality worldwide. Although machine learning models have demonstrated strong predictive performance, limited attention has been given to uncertainty quantification and gender-specific risk factor identification, which are essential for clinically trustwort...
S. Roy, R. Imran, M. R. Haque et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.